The pharmacologic blockade [110,111] or genetic deletion [112] of P2Y12 can improve atherosclerosis lesion development, evidenced by a reduction in plaque size, an increase in fiber content of the plaques, and a decrease in inflammatory molecule levels (e.g., P-/E-selectin) [110,111]. This evidence concerns the gene P2RY12 and atherosclerosis.